Serum fucosylated haptoglobin as a novel prognostic biomarker predicting high-Gleason prostate cancer

Prostate

Volumn 74, Issue 10, 2014, Pages 1052-1058

  Fujita, Kazutoshi ^a   Shimomura, Mayuka ^a   Uemura, Motohide ^a   Nakata, Wataru ^a   Sato, Mototaka ^a   Nagahara, Akira ^a   Nakai, Yasutomo ^a   Takamatsu, Shinji ^a   Miyoshi, Eiji ^a   Nonomura, Norio ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

fucosylation; fucosyltransferase; haptoglobin; prostate cancer; tumor marker

Indexed keywords

BIOLOGICAL MARKER; FUCOSYLATED HAPTOGLOBIN; FUCOSYLTRANSFERASE; HAPTOGLOBIN; MESSENGER RNA; PHYTOHEMAGGLUTININ ANTIBODY; PROSTATE SPECIFIC ANTIGEN; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FUCOSYLATION; GLEASON SCORE; HUMAN; HUMAN CELL; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROSTATECTOMY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SERUM; WESTERN BLOTTING;

FUCOSYLATION; FUCOSYLTRANSFERASE; HAPTOGLOBIN; PROSTATE CANCER; TUMOR MARKER;

AGED; AREA UNDER CURVE; CELL LINE, TUMOR; FUCOSYLTRANSFERASES; HAPTOGLOBINS; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84901649860     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22824     Document Type: Article

References (15)

1. Satkunasivam R, Kulkarni GS, Zlotta AR, Kalnin R, Trachtenberg J, Fleshner NE, Hamilton RJ, Jewett MA, Finelli A,. Pathological, oncologic and functional outcomes of radical prostatectomy following active surveillance. J Urol 2013; 190: 91-95.
2. Eggener SE, Mueller A, Berglund RK, Ayyathurai R, Soloway C, Soloway MS, Abouassaly R, Klein EA, Jones SJ, Zappavigna C, Goldenberg L, Scardino PT, Eastham JA, Guillonneau B,. A multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol 2013; 189 (1 Suppl) S19-S25.
3. Tosoian JJ, Johnbull E, Trock BJ, Landis P, Epstein JI, Partin AW, Walsh PC, Carter HB,. Pathological outcomes in men with low risk and very low risk prostate cancer: Implications on the practice of active surveillance. J Urol 2013; 190: 1218-1223.
4. Miyoshi E, Moriwaki K, Nakagawa T,. Biological function of fucosylation in cancer biology. J Biochem 2008; 143: 725-729. (Pubitemid 351918934)
5. Okuyama N, Ide Y, Nakano M, Nakagawa T, Yamanaka K, Moriwaki K, Murata K, Ohigashi H, Yokoyama S, Eguchi H, Ishikawa O, Ito T, Kato M, Kasahara A, Kawano S, Gu J, Taniguchi N, Miyoshi E,. Fucosylated haptoglobin is a novel marker for pancreatic cancer: A detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation. Int J Cancer 2006; 118: 2803-2808. (Pubitemid 43673360)
6. Kamada Y, Kinoshita N, Tsuchiya Y, Kobayashi K, Fujii H,. Clinica Chimica Acta Reevaluation of a lectin antibody ELISA kit for measuring fucosylated haptoglobin in various conditions. Clin Chim Acta 2013; 417: 48-53.
7. Takeda Y, Shinzaki S, Okudo K, Moriwaki K, Murata K,. Fucosylated haptoglobin is a novel type of cancer biomarker linked to the prognosis after an operation in colorectal cancer. Cancer 2012; 118: 3036-3043.
8. Fujimura T, Shinohara Y, Tissot B, Pang PC, Kurogochi M, Saito S, Arai Y, Sadilek M, Murayama K, Dell A, Nishimura S, Hakomori SI,. Glycosylation status of haptoglobin in sera of patients with prostate cancer vs. benign prostate disease or normal subjects. Int J Cancer 2008; 122: 39-49. (Pubitemid 350209976)
9. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR,. Contemporary trends in low risk prostate cancer: Risk assessment and treatment. J Uro 2007; 178: S14-S19. (Pubitemid 47224952)
10. Magheli A, Hinz S, Hege C, Stephan C, Jung K, Miller K, Lein M,. Prostate specific antigen density to predict prostate cancer upgrading in a contemporary radical prostatectomy series: A single center experience. J Urol 2010; 183: 126-131.
11. Vellekoop A, Loeb S, Folkvaljon Y, Stattin P,. Population-based study of predictors for adverse pathology among candidates for active surveillance with gleason 6 prostate cancer. J Urol 2013; 191: 350-357.
12. Chen CY, Jan YH, Juan YH, Yang CJ, Huang MS, Yu CJ, Yang PC, Hsiao M, Hsu TL, Wong CH,. Fucosyltransferase 8 as a functional regulator of nonsmall cell lung cancer. Proc Natl Acad Sci U S A 2013; 110: 630-635.
13. Thompson S, Dargan E, Turner GA,. Increased fucosylation and other carbohydrate changes in haptoglobin in ovarian cancer. Cancer Lett 1992; 66: 43-48.
14. Ueda K, Katagiri T, Shimada T, Irie S, Sato TA, Nakamura Y, Daigo Y,. Comparative profiling of serum glycoproteome by sequential purification of glycoproteins and 2-nitrobenzensulfenyl (NBS) stable isotope labeling: A new approach for the novel biomarker discovery for cancer. J Proteome Res 2007; 6: 3475-3483. (Pubitemid 47522738)
15. Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM, Slawin KM,. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 2001; 58: 1008-1015. (Pubitemid 34017290)